Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $6,130 MXN
Change Today 0.00 / 0.00%
Volume 0.0
BIIB* On Other Exchanges
As of 4:09 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

biogen idec inc (BIIB*) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/23/15 - $6,151
52 Week Low
04/14/14 - $3,606
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOGEN IDEC INC (BIIB*)

biogen idec inc (BIIB*) Details

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. It provides AVONEX to treat relapsing multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn’s disease; PLEGRIDY to treat relapsing MS; TECFIDERA to treat MS; FAMPYRA to improve walking in adult patients with MS; ALPROLIX to treat hemophilia B; ELOCTATE to treat hemophilia A; RITUXAN for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), as well as two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat severe plaque psoriasis in adult patients. The company’s products that completed Phase III clinical trials comprise ZINBRYTA, a monoclonal antibody in relapsing MS. Its products under Phase III clinical trials consist of TYSABRI for secondary progressive MS and spinal muscular atrophy; ISIS – SMN for spinal muscular atrophy; and GAZYVA for non-Hodgkin's lymphoma. The company’s Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Neublastin for neuropathic pain; TYSABRI for optic neuritis; ANTI-TWAEK for lupus nephritis; BAN2401 and E2609 for Alzheimer’s disease; and GAZYVA for lupus nephritis, as well as Phase IIa clinical trial products include STX-100 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; ISIS – DMPK for myotonic dystrophy; BIIB061 for MS; and Anti-BDCA2 for systemic lupus erythematosus, as well as Phase Ib clinical trial products include BIIB037 for Alzheimer's disease and Anti-C for systemic lupus erythematosus. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.

7,550 Employees
Last Reported Date: 02/4/15
Founded in 1985

biogen idec inc (BIIB*) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $745.2K
Executive Vice President of Research & Develo...
Total Annual Compensation: $766.8K
Executive Vice President of Global Commercial...
Total Annual Compensation: $675.1K
Executive Vice President of Pharmaceutical Op...
Total Annual Compensation: $625.6K
Compensation as of Fiscal Year 2013.

biogen idec inc (BIIB*) Key Developments

Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety Results from Phase 3 Alprolix(R) Paediatric Study

Biogen Idec and Swedish Orphan Biovitrum AB (publ) announced positive top-line results of the Kids B-LONG Phase 3 clinical study that evaluated the safety, efficacy and pharmacokinetics of Alprolix(R) [Coagulation Factor IX (Recombinant), Fc Fusion Protein] in children under age 12 with severe haemophilia B. Alprolix was generally well tolerated and no inhibitors (neutralising antibodies that may interfere with the activity of the therapy) were detected during the study. In this study, once-weekly prophylactic dosing with Alprolix resulted in low bleeding rates. Alprolix is the only approved hemophilia B therapy with prolonged circulation in the body. The successful completion of Kids B-LONG supports applications for paediatric indications in several geographies and is an important step in seeking marketing authorisation for Alprolix in Europe. The European Medicines Agency requires the inclusion of paediatric study data in the initial marketing application for a new haemophilia therapy. Interim results of the Kids B-LONG study helped support the U.S. approval of Alprolix for use in children. Kids B-LONG investigated the safety, efficacy, and pharmacokinetics (measurement of the presence of the drug in a person's body over time) of Alprolix in previously treated children under age 12 with severe haemophilia B. The study's primary endpoint was to evaluate the occurrence of inhibitor development. Secondary endpoints included the overall and spontaneous annualised bleeding rates (ABR), which is the estimated number of yearly bleeding episodes, and the number of injections used to treat bleeding episodes. In the study, children treated prophylactically with Alprolix had an overall median ABR of 1.97. The median ABR for spontaneous joint bleeds was zero. Approximately 33% of participants in the study experienced zero bleeding episodes. Overall, 91.7% of bleeding episodes were controlled by one or two injections of Alprolix. The terminal half-life of Alprolix in the study was 66.5 hours for children under six and 70.3 hours for children six to less than 12 years of age. Additional analyses of the Kids B-LONG study are ongoing, and detailed results will be presented at a future scientific meeting. No inhibitors to Alprolix were detected during the study. Alprolix was generally well tolerated and no cases of serious allergic reactions or vascular thrombotic events were reported in any participants, all of whom had been previously treated with other commercially available factor IX products. No serious adverse events were determined by any investigator to be related to the drug. One adverse event, decreased appetite, was considered related to Alprolix treatment and was reported in one participant. No participant discontinued the study due to an adverse event after receiving Alprolix. The pattern of treatment-emergent adverse events reported was consistent with the population studied and generally consistent with results seen in adolescents and adults in the pivotal Phase 3 B-LONG study.

Biogen Idec Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 02:50 PM

Biogen Idec Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 02:50 PM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States.

Biogen Idec Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 11:00 AM

Biogen Idec Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 11:00 AM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Stuart A. Kingsley, Executive Vice President of Global Commercial Operations.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIIB*:MM $6,130.00 MXN 0.00

BIIB* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $46.50 USD -0.94
Astellas Pharma Inc ¥2,027 JPY +27.00
Bristol-Myers Squibb Co $65.12 USD -0.93
Novo Nordisk A/S kr321.10 DKK +3.10
Takeda Pharmaceutical Co Ltd ¥6,636 JPY +120.00
View Industry Companies

Industry Analysis


Industry Average

Valuation BIIB* Industry Range
Price/Earnings 34.4x
Price/Sales 10.3x
Price/Book 9.2x
Price/Cash Flow 29.6x
TEV/Sales 10.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOGEN IDEC INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at